Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec Biosimilar vs Tresiba in T2D
NCT04955834Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2021; status: recruiting.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04955834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955834.